



Human Radiolabeled Mass Balance (hAME) Studies for Regulatory Submission Part II: Understanding Human Mass Balance and Metabolite Profiling

Fred van Heuveln, PhD, Director of Elemental Analysis at QPS
Diane Grotz, Biotransformation Group Leader at QPS

Join Fred and Diane as they discuss typical analytical aspects of formulation analysis in relation to an hAME study. Reserve your spot today, limited space is available for Part II in this series.

Overview:

An hAME study typically covers two analyses for mass balance, 1) before dosing: the analysis of the formulation and dosing samples, and 2) after dosing: the analysis of the human blood, plasma, feces, and urine samples. Mass balance determines the amount of radioactivity dosed to the subject compared to the amount excreted. This main analytical objective determines the excretion and clearance profiles for total radioactivity in blood, plasma, urine and feces. Another objective is to determine the recovery values (percentage of the dosed radioactivity) which, in relation to the discharge criteria, define when subjects are allowed to leave the clinic.

[Click Here for Key Learning Objectives](#)

Join Us On
May 27th, 2021
(For East Coast US & EU)
9am EDT | 15:00 CEST
To Register Click Below
[Webinar Registration](#)
Or
June 16th, 2021
(For West Coast US)
11am PDT
To Register Click Below
[Webinar Registration](#)

QPS has CLIA-certified and GLP-compliant laboratories ready to fast-track your novel coronavirus and COVID-19 RT-qPCR/QPCR and Serological Assays and vaccine development programs. Since 1995, QPS has provided discovery, preclinical, and clinical drug development services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. For more information, visit www.qps.com or email info@qps.com.